## Estimating changes in antibiotic consumption with the introduction of doxycycline post-exposure prophylaxis in the United States

3 4

5

6 7 Kirstin I. Oliveira Roster<sup>1</sup> and Yonatan H. Grad\*<sup>1</sup>

- <sup>1.</sup> Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston MA
- \* Correspondence: ygrad@hsph.harvard.edu
- 8 9 10

## 11 Abstract

12 Doxycycline as post-exposure prophylaxis (doxy-PEP) reduces the risk of gonorrhea, chlamydia, and syphilis in studies of men who have sex with men (MSM) and 13 14 transgender women (TGW) on HIV Pre-exposure Prophylaxis (PrEP) and people living with HIV (PLWH)). Doxy-PEP is an important tool to address the increasing burden of 15 sexually transmitted infections (STIs), but there is concern that increased consumption 16 of doxycycline may drive antimicrobial resistance. We estimated the expected increase 17 in antibiotic use in the US under several doxy-PEP prescribing scenarios. We 18 accounted for doses of antibiotics that may be averted due to the prevention of 19 20 chlamydia, gonorrhea, and syphilis infections by doxy-PEP. Under a scenario of 75% adoption among the eligible population, with rates of consumption similar to the 21 DoxyPEP trial population, monthly antibiotic consumption would increase by around 22 2.52 million doses, driven by doxy-PEP consumption of 2.58 million doses and less 62.1 23 thousand antibiotic doses that would otherwise have been used for chlamydia, 24 gonorrhea, and syphilis treatment. 25

26 27 medRxiv preprint doi: https://doi.org/10.1101/2023.09.20.23295787; this version posted September 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Doxycycline as post-exposure prophylaxis (doxy-PEP), a 200mg dose of doxycycline taken within 72 hours of condomless sex, reduces the risk of gonorrhea, chlamydia, and syphilis in studies of men who have sex with men (MSM) and transgender women (TGW) on HIV Pre-exposure Prophylaxis (PrEP) and people living with HIV (PLWH)) (1,2) . Local and state departments of public health have published clinical guidelines for prescribing doxy-PEP (e.g., (3,4)) and national guidelines are expected soon.

- Doxy-PEP is an important tool to address the increasing burden of sexually transmitted infections (STIs), but there is concern that increased consumption of doxycycline may drive antimicrobial resistance, including doxycycline resistant *N. gonorrhoeae*, *Staphylococcus aureus*, and *Streptococcus pneumoniae* (5–8).
- 39

34

How may antibiotic consumption change with the adoption of doxy-PEP? Addressing 40 this question may inform considerations of the risks of antimicrobial resistance and the 41 benefits of STI prevention. Here, we estimated the expected increase in antibiotic 42 consumption in the US under several doxy-PEP prescribing scenarios. We accounted 43 for defined daily doses (DDDs), hereafter simply referred to as doses, of antibiotics that 44 may be averted due to the prevention of chlamydia (doxycycline), gonorrhea 45 (ceftriaxone), and syphilis (penicillin) infections by doxy-PEP, with relative risk estimates 46 47 as reported in the US trial (1) (Supplemental Table S1).

48

We estimated that 0.86 million MSM may be eligible for a doxy-PEP prescription under 49 the enrollment criteria of the DoxyPEP trial (1) (0.53 million PLWH and 0.33 million HIV 50 PrEP users; Supplemental Table S1). Under a scenario of 75% adoption among this 51 population (**Supplement**), with rates of consumption similar to the DoxyPEP trial 52 53 population (4 doses per person-month)(1), monthly antibiotic consumption would increase by around 2.52 million doses, driven by doxy-PEP consumption of 2.58 million 54 doses and less 62.1 thousand antibiotic doses that would otherwise have been used for 55 chlamydia, gonorrhea, and syphilis treatment (Supplemental Table S2). Under a 56 scenario of widespread prescribing of doxy-PEP to the entire eligible population (100%) 57 adoption), monthly antibiotic consumption would be expected to increase by 3.36 million 58 doses (Supplemental Table S4). 59

A study of ten prescribing strategies based on a patient's PrEP use, HIV status, and 60 bacterial STI history projected substantial variation across the strategies in the number 61 of infections averted per person taking doxy-PEP (9). The prescribing criterion with the 62 lowest number needed to treat to prevent a chlamydia infection was a diagnosis of two 63 bacterial STIs within six months. Adoption of this strategy with 75% uptake among MSM 64 on HIV PrEP and PLWH would lead to an increase in monthly antibiotic consumption of 65 66 0.28 million doses, while widespread (100%) adoption would lead to an increase of 0.37 million doses (Supplemental Table S5). Among bacterial STI history-based prescribing 67 strategies, the increase in antibiotic consumption was directly related to the size of the 68 treated population (9); prescribing doxy-PEP to individuals with a diagnosis of at least 69 two concurrent bacterial STIs would be expected to result in the smallest population 70 treated and also the smallest increase in antibiotic consumption (0.18 and 0.24 million 71 72 doses per month with 75% and 100% adoption, respectively; Supplement, Equations 2.1-2.3, Table S5). 73

medRxiv preprint doi: https://doi.org/10.1101/2023.09.20.23295787; this version posted September 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

74

A net zero change in doxycycline consumption, where doxy-PEP consumption is balanced with the number of averted doxycycline doses for chlamydia treatment, would require restricting prescriptions to a group with incidence of 7.8 infections per personyear, while maintaining similar levels of monthly doxy-PEP consumption and reductions in chlamydia infection risk reported for HIV PrEP users (**Supplement, Equations 3.1**-**3.3**).

81 82 Our estimates were based on first-order, short-term use of doxy-PEP. We did not 83 consider the indirect protective effects of doxy-PEP among non-users, which at least 84 initially are expected to reduce bacterial STL incidence (10). We relied on the average

initially are expected to reduce bacterial STI incidence (10). We relied on the average 84 estimates of doxy-PEP consumption and relative risk of infection reported in the 85 DoxyPEP trial (1) for all strategies, though these measures likely vary depending on the 86 population treated. Our estimates of antibiotic doses avoided by doxy-PEP considered 87 treatment for uncomplicated chlamydia and gonorrhea and primary syphilis and not for 88 disseminated gonorrhea or for secondary or tertiary disease. Future research is needed 89 90 to understand consumption and risk among more granular groups and to identify strategies that minimize the number of antibiotic doses consumed (not only the number 91 needed to treat) while preventing the greatest number of STIs. 92

These estimates suggest that doxycycline consumption is expected to increase with the introduction of doxy-PEP, even when accounting for the reduction in antibiotics used to treat chlamydia, gonorrhea, and syphilis, though the extent of the increase will depend on the size of the population that uses doxy-PEP. Monitoring the changes in the extent of antibiotic consumption, along with changes in disease incidence and the burden of resistance, will be important to understand doxy-PEP's impact.

100

93

Funding Statement: This work was supported by National Institute of Allergy and Infectious Diseases (grant numbers R01 Al132606 and R01 Al153521) and CDC contract number 200-2016-91779 to Y. H. G. The findings, conclusions, and views expressed are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC). medRxiv preprint doi: https://doi.org/10.1101/2023.09.20.23295787; this version posted September 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

## 106 **References**

107

- Luetkemeyer AF, Donnell D, Dombrowski JC, Cohen S, Grabow C, Brown CE, et al.
   Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. N Engl J Med. 2023;388(14):1296–306.
- 111 2. Molina JM, Bercot, Beatrice, Assoumou L, Michele, Algarte-Genin, Rubenstein, Emma,
- Pialoux, Gilles, et al. ANRS 174 DOXYVAC: AN OPEN-LABEL RANDOMIZED TRIAL TO
   PREVENT STIS IN MSM ON PrEP CROI Conference. In 2023 [cited 2023 Sep 8]. Available
   from: https://www.croiconference.org/abstract/anrs-174-doxyvac-an-open-label-randomized trial-to-prevent-stis-in-msm-on-prep/
- California Department of Public Health. Doxycycline Post-Exposure Prophylaxis (doxy-PEP)
   for the Prevention of Bacterial Sexually Transmitted Infections (STIs). State of California
- 118 Health and Human Services Agency. 2023 Apr 28;
- 4. San Francisco Department of Public Health. Health Update: Doxycycline Post-Exposure
   Prophylaxis Reduces Incidence of Sexually Transmitted Infections. SFDPH Population Health
   Division. 2022 Oct 20;
- Mortimer TD, Grad YH. A Genomic Perspective on the Near-term Impact of Doxycycline Postexposure Prophylaxis on Neisseria gonorrhoeae Antimicrobial Resistance. Clin Infect Dis. 2023 May 4;ciad279.
- 6. Whiley DM, Tickner JA, Kundu RL, Hogan TR, Hal SJ van, Lahra MM. Selection of Neisseria
  gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis. Lancet
  Infect Dis. 2023 Aug 1;23(8):e268–9.
- Kong FYS, Kenyon C, Unemo M. Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections. J Antimicrob Chemother. 2023 Jul 1;78(7):1561–8.
- Truong R, Tang V, Grennan T, Tan DHS. A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora. JAC-Antimicrob Resist. 2022 Feb 1;4(1):dlac009.
- Traeger MW, Mayer KH, Krakower DS, Gitin S, Jenness SM, Marcus JL. Potential impact of doxycycline post-exposure prophylaxis prescribing strategies on incidence of bacterial sexually transmitted infections. Clin Infect Dis Off Publ Infect Dis Soc Am. 2023 Aug 18;ciad488.
- 138 10. Reichert E, Grad YH. Resistance and prevalence implications of doxycycline post-exposure
   prophylaxis for gonorrhea prevention in men who have sex with men: a modeling study
   [Internet]. medRxiv; 2023 [cited 2023 Sep 8]. p. 2023.04.24.23289033. Available from:
- 141 https://www.medrxiv.org/content/10.1101/2023.04.24.23289033v1

142